Atea Pharma's COVID-19 treatment fails to meet study goal

mediabest

(Reuters) – Atea Pharmaceuticals said on Tuesday a mid-stage trial testing its experimental COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in patients with mild or moderate disease.

Source: Read Full Article

Related posts:
  1. Hungary reports record 8,312 coronavirus infections in 24 hours
  2. COVID-19 situation in Paris area extremely tense: French PM
  3. Japan government spokesman says ministers share urgency over record COVID spike
  4. British Columbia mandates vaccines for staff of long-term care and assisted living homes
  5. U.S. to begin offering COVID-19 vaccine booster shots in September